Compare Stocks: AZTR, SEOVF, SGMO, and BRNS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZTR Azitra	$0.13 -1.6%	$0.15	$0.10 ▼ $1.09	$8M	-1.05	786,708 shs	310,361 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.69	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
SEOVF Sernova Biotherapeutics	$0.08 -0.4%	$0.08	$0.06 ▼ $0.14	$30.59M	0.89	144,305 shs	3,358 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZTR Azitra	-1.59%	-1.59%	-27.06%	-8.52%	-82.37%
BRNS Barinthus Biotherapeutics	0.00%	0.00%	-5.36%	+18.04%	-50.99%
SEOVF Sernova Biotherapeutics	-0.37%	+3.99%	-17.90%	-10.33%	-38.72%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-89.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZTR Azitra	$0.13 -1.6%	$0.15	$0.10 ▼ $1.09	$8M	-1.05	786,708 shs	310,361 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.69	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
SEOVF Sernova Biotherapeutics	$0.08 -0.4%	$0.08	$0.06 ▼ $0.14	$30.59M	0.89	144,305 shs	3,358 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZTR Azitra	-1.59%	-1.59%	-27.06%	-8.52%	-82.37%
BRNS Barinthus Biotherapeutics	0.00%	0.00%	-5.36%	+18.04%	-50.99%
SEOVF Sernova Biotherapeutics	-0.37%	+3.99%	-17.90%	-10.33%	-38.72%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-89.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZTR Azitra	0.00	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside

Current Analyst Ratings Breakdown

Latest AZTR, SEOVF, SGMO, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZTR Azitra	$10K	787.19	N/A	N/A	$0.35 per share	0.37
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZTR Azitra	-$10.95M	N/A	N/A	N/A	N/A	N/A	-205.46%	-161.66%	11/11/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
SEOVF Sernova Biotherapeutics	-$11.24M	-$0.04	N/A	N/A	N/A	N/A	N/A	-1,111.49%	12/18/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A

Latest AZTR, SEOVF, SGMO, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	BRNS Barinthus Biotherapeutics	-$0.27	N/A	N/A	N/A	$0.22 million	N/A
9/10/2026	Q3 2026	SEOVF Sernova Biotherapeutics	-$0.0050	-$0.01	-$0.0050	-$0.01	N/A	N/A
8/12/2026	Q2 2026	AZTR Azitra	-$0.1150	-$0.17	-$0.0550	-$0.17	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZTR Azitra	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZTR Azitra	N/A	4.86	4.86
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
SEOVF Sernova Biotherapeutics	N/A	0.03	0.03
SGMO Sangamo Therapeutics	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZTR Azitra	11.16%
BRNS Barinthus Biotherapeutics	25.20%
SEOVF Sernova Biotherapeutics	N/A
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
AZTR Azitra	0.28%
BRNS Barinthus Biotherapeutics	8.50%
SEOVF Sernova Biotherapeutics	N/A
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZTR Azitra	13	60.60 million	60.43 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
SEOVF Sernova Biotherapeutics	N/A	377.64 million	N/A	Not Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable

AZTR, SEOVF, SGMO, and BRNS Headlines

Recent News About These Companies

Sangamo Therapeutics Completes Fabry Gene Therapy Asset Sale

September 21, 2026 | tipranks.com

Sangamo Therapeutics stock falls after Nasdaq delisting to OTC market

September 19, 2026 | ad-hoc-news.deA

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

July 20, 2026 | tipranks.com

Sangamo Therapeutics Inc SGMO

July 7, 2026 | morningstar.comM

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

June 24, 2026 | markets.businessinsider.com

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets

June 24, 2026 | seekingalpha.com

Sangamo Therapeutics files for Chapter 11 bankruptcy

June 24, 2026 | msn.com

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales

June 23, 2026 | tipranks.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...

May 16, 2026 | finance.yahoo.com

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period

May 16, 2026 | tipranks.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2026 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 | globenewswire.com

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 11, 2026 | markets.businessinsider.com

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

May 5, 2026 | finanznachrichten.de

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026 | globenewswire.com

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

April 29, 2026 | finance.yahoo.com

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

April 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTR, SEOVF, SGMO, and BRNS Company Descriptions

Azitra NYSEAMERICAN:AZTR

$0.13 0.00 (-1.59%)

Closing price 10/9/2026 04:10 PM Eastern

Extended Trading

$0.13 0.00 (-0.69%)

As of 10/9/2026 07:53 PM Eastern

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 10/8/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.08 0.00 (-0.37%)

As of 10/9/2026 03:55 PM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 10/8/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZTR, SEOVF, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZTR, SEOVF, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZTR, SEOVF, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTR, SEOVF, SGMO, and BRNS Company Descriptions

Azitra NYSEAMERICAN:AZTR

Barinthus Biotherapeutics NASDAQ:BRNS

Sernova Biotherapeutics OTCMKTS:SEOVF

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZTR, SEOVF, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZTR, SEOVF, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZTR, SEOVF, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTR, SEOVF, SGMO, and BRNS Company Descriptions

Azitra NYSEAMERICAN:AZTR

Barinthus Biotherapeutics NASDAQ:BRNS

Sernova Biotherapeutics OTCMKTS:SEOVF

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools